Semaglutide vs Tirzepatide: Complete Comparison Guide

Two Approaches to GLP-1 Therapy

Semaglutide and tirzepatide represent two generations of incretin-based weight loss therapy. While both are administered as weekly subcutaneous injections and produce significant weight loss, they differ in their mechanism of action, which translates into distinct clinical profiles.

Semaglutide is a GLP-1 receptor agonist -- it mimics a single gut hormone (GLP-1) to reduce appetite and regulate blood sugar. Tirzepatide is a dual GIP/GLP-1 receptor agonist -- it activates two incretin receptors simultaneously, potentially offering complementary metabolic benefits.

Mechanism of Action

Semaglutide

Single GLP-1 Receptor Agonist

-- Activates GLP-1 receptors in the brain, gut, and pancreas
-- Reduces appetite through hypothalamic signalling
-- Delays gastric emptying to prolong satiety
-- Enhances glucose-dependent insulin secretion
-- Well-established safety profile with extensive long-term data

Tirzepatide

Dual GIP + GLP-1 Receptor Agonist

-- Activates both GIP and GLP-1 receptors simultaneously
-- GIP receptor activation may enhance fat metabolism
-- Complementary appetite suppression through dual pathways
-- Enhanced insulin sensitivity through combined incretin effect
-- Newer medication with growing clinical evidence base

Head-to-Head Comparison

Feature	Semaglutide	Tirzepatide
Drug Class	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Administration	Once-weekly injection	Once-weekly injection
Dose Range	0.25mg - 2.4mg	2.5mg - 15mg
Titration Period	16 weeks to maintenance	20 weeks to maintenance
Weight Loss Efficacy	Significant, well-documented	Published data suggests greater mean weight loss
HbA1c Reduction	Significant improvement	Published data suggests greater HbA1c reduction
GI Side Effects	Nausea ~44%, generally mild	Similar GI profile, nausea ~25-30%
Cardiovascular Data	Positive outcomes (SELECT trial, 2023)	Ongoing cardiovascular outcomes trials
Long-Term Safety Data	Extensive (years of post-market data)	Growing (newer to market)
Cost in Nigeria	Contact for pricing	Generally higher (contact for pricing)
Branded Versions	Ozempic^®, Wegovy^®	Mounjaro^®, Zepbound^®

Side Effect Profiles

Both medications share similar gastrointestinal side effects, which is expected given their shared GLP-1 receptor agonist activity. However, published clinical data suggests some differences in the frequency and severity of these effects.

Both Share

Nausea (most common, usually transient)
Diarrhoea
Vomiting
Constipation
Abdominal discomfort
Headache
Injection site reactions

Key Differences

Semaglutide: Higher reported nausea rates, more cardiovascular outcome data
Tirzepatide: Lower reported nausea rates in some studies, potentially better glycaemic control in diabetic patients
Both: Precautionary thyroid C-cell tumour warning (animal studies)
Both: Contraindicated in MTC/MEN2 history

Cost Considerations in Nigeria

Cost is a significant factor for many patients in Nigeria. Both medications represent a meaningful financial commitment, and understanding the cost difference can help inform your decision.

General Cost Guidance

-- Semaglutide is generally the more affordable option, making it accessible to a wider range of patients
-- Tirzepatide is typically priced higher due to its newer status and dual-action mechanism
-- Both are available as compounded formulations through licensed providers in Nigeria
-- Contact for current pricing -- rates vary based on dose and treatment duration

Many patients begin with semaglutide due to its established track record and lower cost, then discuss switching to tirzepatide with their doctor if they desire enhanced results. Your healthcare provider can help you weigh the cost-benefit analysis based on your specific health profile and goals.

How to Choose Between Them

The choice between semaglutide and tirzepatide should be made in consultation with a qualified healthcare provider who can evaluate your complete medical history, goals, and individual risk factors.

Consider Semaglutide If:

You want an extensively studied medication with years of safety data
Budget is a primary consideration
You have cardiovascular risk factors (positive SELECT trial data)
You are starting GLP-1 therapy for the first time

Consider Tirzepatide If:

You have type 2 diabetes alongside obesity (dual metabolic benefit)
Published evidence suggests you may benefit from the dual-action approach
You have tried semaglutide and want to explore a different approach
Your doctor recommends it based on your specific clinical profile

Bottom line: Both semaglutide and tirzepatide are highly effective GLP-1-based weight loss therapies supported by substantial clinical evidence. The "best" choice depends on your individual medical history, treatment goals, budget, and your doctor's clinical judgement. There is no universally superior option -- only the one that is most appropriate for you.

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(4):327-340. PMID: 35658024
Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
Drucker DJ. GIP and GLP-1 as incretin hormones: Lessons from single and double incretin receptor knockout mice. Best Pract Res Clin Endocrinol Metab. 2004;18(4):531-554. PMID: 15533774
Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide. Lancet. 2021;398(10295):143-155. PMID: 34186022
Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol. 2022;10(2):75-77. PMID: 34951953
Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes. Lancet. 2021;397(10278):971-984. PMID: 33667417
Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity. Nat Med. 2022;28(10):2083-2091. PMID: 36216945
Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes. Diabetes Ther. 2021;12(2):405-413. PMID: 33369721

Medical Review

This article was reviewed by the Semaglutide.ng team for clinical accuracy. Content is based on published peer-reviewed research and does not constitute medical advice. Individual treatment decisions should be made with a qualified healthcare provider.

Last reviewed: February 2026

Semaglutide vs Tirzepatide